SYK
SKI-O-703
– Selective SYK for autoimmune disorders
– Proposed indications of SKI-O-703 include rheumatoid arthritis (RA), immune thrombocytopenia (ITP), systemic lupus erythematosus(SLE), autoimmune hemolytic anemia (AIHA) and IgA nephropathy (IgAN), as well as indications such as atopic dermatitis, asthma, allergies, and psoriasis.
– Selective SYK for autoimmune disorders
– Proposed indications of SKI-O-703 include rheumatoid arthritis (RA), immune thrombocytopenia (ITP), systemic lupus erythematosus(SLE), autoimmune hemolytic anemia (AIHA) and IgA nephropathy (IgAN), as well as indications such as atopic dermatitis, asthma, allergies, and psoriasis.
FLT3
SKI-G-801
- Intravenous selective FLT3 inhibitor for acute myeloid leukemia
- SKI-G-801 is a highly potent and selective inhibitor against all clinically-known mutations in FLT3. Its superiority compared to any known FLT3 inhibitors
- Intravenous selective FLT3 inhibitor for acute myeloid leukemia
- SKI-G-801 is a highly potent and selective inhibitor against all clinically-known mutations in FLT3. Its superiority compared to any known FLT3 inhibitors
EGFR
GNS-1480 (Lazertinib,YH25448)
– Oral 3rd-generation EGFR inhibitor for non-small cell lung cancer (NSCLC)
– Targeting various single and double mutants of EGFR including T790M/L858R and T790M/Del19
– Oral 3rd-generation EGFR inhibitor for non-small cell lung cancer (NSCLC)
– Targeting various single and double mutants of EGFR including T790M/L858R and T790M/Del19
4th–generation EGFR inhibitor program
– Targeting additional mutation of EGFR at amino acid position 797 (C797S), which is a main reason for drug resistance for 3rd generation EGFR inhibitors including Osmertinib®
Press Release
Yuhan signs $1.25 billion licensing deal with Janssen
Lasertinib(GNS-1480), discovered by Genosco, was out-licensed to Janssen.
Early results from a 3rd gen EGFR-TKI in advanced NSCLC
Dr. Cho speaks with ecancer at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting about a phase I/II trial of lazertinib(GNS-1480, YH25448), a highly selective and irreversible investigational 3rd-generation EGFR-TKI.
Current Partners
